Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse…
Olympism365 Summit: IOC President calls on global participants to join forces to use sport to serve society
04 June 2025 - As the Olympism365 Summit: Sport for a Better World kicked…
